Clinical TrialsThe OPGx-BEST1 IND has been cleared, and a first-in-human trial is set to start, which could lead to meaningful vision improvement and become a major value driver for IRD.
Financial PositionThe company's cash position is strong, with $32.4 million in cash and equivalents, and additional funding may arise, supporting operations into the future.
Strategic PartnershipsThe strategic partnership with the Global RDH12 Alliance is seen as a validation of tangible support from the inherited retinal disease community, potentially driving future adoption of Opus' gene therapies.